IP Library › Granted Patent US 7,083,790
Granted Patent B2
US 7,083,790 · App. 10/461,787 · Granted Aug 1, 2006

Extracellular serine protease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,083,790
App. No.
10/461,787
Granted
Aug 1, 2006
Kind
B2
Abstract

The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention.

Claims (3)

1. A method of eliciting an immune response in an individual against TADG-14 protein comprising the amino acid sequence of SEQ ID No. 7, comprising the step of:

inoculating an individual with a TADG-14 protein fragment consisting of the amino acid sequence selected from the group consisting of SEQ ID Nos. 17, 18, 41, 42, 47, 48, 53, 56 and 64, wherein said TADG-14 protein fragment lacks TADG-14 protease activity, wherein said inoculation with said TADG-14 protein fragment elicits an immune response against said TADG-14n said individual.

2. The method of claim 1 , wherein said individual has ovarian cancer, prostate cancer, breast cancer or colon cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2017
From: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
To: BIOVENTURES, LLC
Reel/Frame 044037/0496 →